NCT02057237View on ClinicalTrials.gov

A Safety and Feasibility Study of Mitotane in Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

October 31, 2015

Conditions
Prostate Cancer
Interventions
DRUG

Mitotane

Mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance every 3rd day by 0.5 g up to a maximal dose of 5.0 g and then adjusted according to blood concentrations monthly and tolerability, up to a maximum of 10g daily

Trial Locations (1)

M5G 2M9

University Health Network, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT02057237 - A Safety and Feasibility Study of Mitotane in Prostate Cancer | Biotech Hunter | Biotech Hunter